| Bioactivity | SARS-CoV-2-IN-35 is a potent and orally active SARS-CoV-2 M pro inhibitor with a Ki value of 12.1 nM. SARS-CoV-2-IN-35 can be used in research of COVID-19[1]. |
| In Vivo | SARS-CoV-2-IN-35 (compound 5; 10 mg/kg; p.o.) has good oral utilization in Wistar-Han rats[1]. Animal Model: |
| Name | SARS-CoV-2-IN-35 |
| CAS | 2757763-47-4 |
| Formula | C29H34F3N5O5S |
| Molar Mass | 621.67 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Owen DR, et, al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021 Dec 24;374(6575):1586-1593. |
SARS-CoV-2-IN-35
CAS: 2757763-47-4 F: C29H34F3N5O5S W: 621.67
SARS-CoV-2-IN-35 is a potent and orally active SARS-CoV-2 M pro inhibitor with a Ki value of 12.1 nM. SARS-CoV-2-IN-35 c
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.